CB34 + CB48

CB34 + CB48 is a bispecific antibody combination program currently in the discovery phase, developed by Cartography Biosciences for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The program leverages the company's proprietary ATLAS and SUMMIT platforms, which utilize single-cell profiling and computational analysis to identify precise, tumor-specific antigen pairs. By targeting these novel antigens, the bispecific antibody aims to selectively eliminate cancer cells while sparing healthy tissue, potentially offering a wider therapeutic window than traditional therapies. The specific molecular targets of the CB34 and CB48 components have not been publicly disclosed.